Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지
DOI QR코드

DOI QR Code

What Is a Balanced Way of Anticoagulation for Efficacy and Safety in High-Risk Elderly Patients With Atrial Fibrillation?

  • Daehoon Kim (Division of Cardiology, Department of Internal Medicine, Severance Cardiovascular Hospital, Yonsei University College of Medicine)
  • Received : 2024.06.03
  • Accepted : 2024.06.17
  • Published : 2024.07.01
Download PDF
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Kim D, Yang PS, Jang E, et al. 10-Year nationwide trends of the incidence, prevalence, and adverse outcomes of non-valvular atrial fibrillation nationwide health insurance data covering the entire Korean population. Am Heart J 2018;202:20-6. https://doi.org/10.1016/j.ahj.2018.04.017
  2. Kim D, Yang PS, Joung B. Optimal rhythm control strategy in patients with atrial fibrillation. Korean Circ J 2022;52:496-512. https://doi.org/10.4070/kcj.2022.0078
  3. Kim M, Kim J, Kim JB, et al. Association of gender with clinical outcomes in a contemporary cohort of patients with atrial fibrillation receiving oral anticoagulants. Korean Circ J 2022;52:593-603. https://doi.org/10.4070/kcj.2021.0399
  4. Joung B, Lee JM, Lee KH, et al. 2018 Korean guideline of atrial fibrillation management. Korean Circ J 2018;48:1033-80. https://doi.org/10.4070/kcj.2018.0339
  5. Kim D, Yang PS, Sung JH, et al. Effectiveness and Safety of Anticoagulation Therapy in Frail Patients With Atrial Fibrillation. Stroke 2022;53:1873-82. https://doi.org/10.1161/STROKEAHA.121.036757
  6. Sabbag A, Yao X, Siontis KC, Noseworthy PA. Anticoagulation for stroke prevention in older adults with atrial fibrillation and comorbidity: current evidence and treatment challenges. Korean Circ J 2018;48:873-89. https://doi.org/10.4070/kcj.2018.0261
  7. Okumura K, Akao M, Yoshida T, et al. Low-dose edoxaban in very elderly patients with atrial fibrillation. N Engl J Med 2020;383:1735-45. https://doi.org/10.1056/NEJMoa2012883
  8. Yao X, Shah ND, Sangaralingham LR, Gersh BJ, Noseworthy PA. Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction. J Am Coll Cardiol 2017;69:2779-90. https://doi.org/10.1016/j.jacc.2017.03.600
  9. Chan YH, Chao TF, Chen SW, et al. Clinical outcomes in elderly atrial fibrillation patients at increased bleeding risk treated with very low dose vs. regular-dose non-vitamin K antagonist oral anticoagulants: a nationwide cohort study. Eur Heart J Cardiovasc Pharmacother 2023;9:681-91.
  10. Kim JY, Kim J, Park SJ, et al. Optimal dose of edoxaban for very elderly atrial fibrillation patients at high risk of bleeding: the LEDIOS registry. Korean Circ J 2024;54:398-406. https://doi.org/10.4070/kcj.2024.0084